Literature DB >> 7701272

Clinical features and outcome of child and adolescent schizophrenia.

J S Werry1, J M McClellan, L K Andrews, M Ham.   

Abstract

Subjects admitted 12 months or more previously to two child and adolescent psychiatric units in New Zealand and the United States with a diagnosis of non-organic, nonautistic psychosis, were contacted and those who received a DSM-III-R diagnosis of schizophrenia were studied (n = 33 [New Zealand] and n = 24 [United States]). Premorbid and first-episode data were obtained from the admission record using global clinical measures of moderate reliability, outcome diagnosis and status by interviews, and professional and family reports. Mean ages at onset were 13.9 (New Zealand) and 15.6 (United States). Premorbid and clinical features resembled those in adult schizophrenia, though there were probable quantitative differences. At outcome (mean interval = 4 years) few subjects were symptom-free or independent, and mean global assessment of functioning had fallen from 55 to 40. Outcome was much worse in schizophrenia than bipolar disorder. Despite a 59 percent attrition rate and higher rates of initial misdiagnosis in the United States, and some demographic differences, New Zealand and United States samples resembled each other clinically and in outcome. Initial misdiagnosis of bipolar disorder as schizophrenia was not due to minimizing mood symptoms, which were common in both disorders. Within this age range (mostly 11-17), age at onset had only minor effects. Outcome was best predicted by premorbid personality.

Entities:  

Mesh:

Year:  1994        PMID: 7701272     DOI: 10.1093/schbul/20.4.619

Source DB:  PubMed          Journal:  Schizophr Bull        ISSN: 0586-7614            Impact factor:   9.306


  14 in total

1.  The Maudsley early onset schizophrenia study. Predictors of psychosocial outcome at 4-year follow-up.

Authors:  Nora S Vyas; Michael Hadjulis; Apostolos Vourdas; Patrick Byrne; Sophia Frangou
Journal:  Eur Child Adolesc Psychiatry       Date:  2007-10       Impact factor: 4.785

2.  Late-onset schizophrenia and the delusional disorders in old age.

Authors:  H Häfner
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  1997       Impact factor: 5.270

3.  Associations among obesity, acute weight gain, and response to treatment with olanzapine in adolescent schizophrenia.

Authors:  David E Kemp; Christoph U Correll; Mauricio Tohen; Melissa P Delbello; Stephen J Ganocy; Robert L Findling; Kiki Chang
Journal:  J Child Adolesc Psychopharmacol       Date:  2013-10-10       Impact factor: 2.576

Review 4.  Some remarks on etiological aspects of early-onset schizophrenia.

Authors:  C Eggers
Journal:  Eur Child Adolesc Psychiatry       Date:  1999       Impact factor: 4.785

5.  Exploratory eye movements to pictures in childhood-onset schizophrenia and attention-deficit/hyperactivity disorder (ADHD).

Authors:  C Karatekin; R F Asarnow
Journal:  J Abnorm Child Psychol       Date:  1999-02

6.  Premorbid adjustment and remission of positive symptoms in first-episode psychosis.

Authors:  G P Amminger; F Resch; R Mutschlechner; M H Friedrich; E Ernst
Journal:  Eur Child Adolesc Psychiatry       Date:  1997-12       Impact factor: 4.785

7.  Components of visual search in childhood-onset schizophrenia and attention-deficit/hyperactivity disorder.

Authors:  C Karatekin; R F Asarnow
Journal:  J Abnorm Child Psychol       Date:  1998-10

8.  Olanzapine approved for the acute treatment of schizophrenia or manic/mixed episodes associated with bipolar I disorder in adolescent patients.

Authors:  Ann E Maloney; Linmarie Sikich
Journal:  Neuropsychiatr Dis Treat       Date:  2010-11-10       Impact factor: 2.570

Review 9.  Should cognitive deficit be a diagnostic criterion for schizophrenia?

Authors:  Ralph Lewis
Journal:  J Psychiatry Neurosci       Date:  2004-03       Impact factor: 6.186

10.  Evidence-based family psychoeducational interventions for children and adolescents with psychotic disorders.

Authors:  Robin Edward Gearing
Journal:  J Can Acad Child Adolesc Psychiatry       Date:  2008
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.